Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Daiichi Sankyo
Baxter
Citi

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 9,821,074

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,821,074
Title:Pyrrolobenzodiazepines and conjugates thereof
Abstract: Conjugate compounds of formula (A): ##STR00001## wherein: R.sup.2 is ##STR00002## where R.sup.36a and R.sup.36b are independently selected from H, F, C.sub.1-4 saturated alkyl, C.sub.2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C.sub.1-4 alkyl amido and C.sub.1-4 alkyl ester or, when one of R.sup.36a and R.sup.36b is H, the other is selected from nitrile and a C.sub.1-4 alkyl ester; R.sup.6 and R.sup.9 are independently selected from H, R, OH, OR, SH, SR, NH.sub.2, NHR, NRR\', NO.sub.2, Me.sub.3Sn and halo; R.sup.7 is independently selected from H, R, OH, OR, SH, SR, NH.sub.2, NHR, NRR\', NO.sub.2, Me.sub.3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: ##STR00003## ##STR00004## L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; R.sup.A4 is a C.sub.1-6 alkylene group; either (a) R.sup.10 is H, and R.sup.11 is OH, OR.sup.A, where R.sup.A is C.sub.1-4 alkyl; or (b) R.sup.10 and R.sup.11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R.sup.10 is H and R.sup.11 is OSO.sub.zM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R\' are each independently selected from optionally substituted C.sub.1-12 alkyl, C.sub.3-20 heterocyclyl and C.sub.5-20 aryl groups, and optionally in relation to the group NRR\', R and R\' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R.sup.16, R.sup.17, R.sup.19, R.sup.20, R.sup.21 and R.sup.22 are as defined for R.sup.6, R.sup.7, R.sup.9, R.sup.10, R.sup.11 and R.sup.2 respectively; wherein Z is CH or N; wherein T and T\' are independently selected from a single bond or a C.sub.1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X\' is 3 to 12 atoms; and X and X\' are independently selected from O, S and N(H).
Inventor(s): Howard; Philip Wilson (London, GB), Flygare; John A. (South San Francisco, CA), Pillow; Thomas (South San Francisco, CA), Wei; Binqing (South San Francisco, CA)
Assignee: Genentech, Inc. (San Francisco, CA) MedImmue Limited (GB)
Application Number:14/208,374
Patent Claims:see list of patent claims

Details for Patent 9,821,074

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Genentech, Inc. (San Francisco, CA) MedImmue Limited (GB) 2037-11-25 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
Colorcon
McKesson
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.